ArticleBMC medical imaging2026
The diagnostic value of radiomics based on two-dimensional ultrasound in staging diabetic nephropathy.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo stage diabetic nephropathy (DN) using two-dimensional ultrasound (B-mode) radiomics combined with clinical features.
methodsDN was classified into early, middle, and late stages. Two-dimensional ultrasound images and clinical biochemical data from patient records were analyzed. Radiomics features were extracted from images, and two classification scenarios were examined: early vs. middle to late DN, and early to middle vs. late DN. Lasso logistic regression was used to create nomograms integrating clinical and radiomics data. The performance of these nomograms was evaluated using ROC curves, calibration, and decision curves.
results242 patients with renal biopsy (early DN: n = 102; middle DN: n = 53; late DN: n = 87) were included and randomly split into training (n = 169) and validation (n = 73) sets. For early vs. middle to late DN, the nomograms achieved AUCs of 0.939 and 0.876, with sensitivities of 0.882 and 0.816, specificities of 0.896 and 0.686, and F1 scores of 0.905 and 0.775 in training and validation cohorts, respectively. For early to middle vs. late DN, AUCs were 0.951 and 0.955, with sensitivities of 0.767 and 0.889, specificities of 0.917 and 0.913, and F1 scores of 0.800 and 0.873, respectively. Decision curve analysis confirmed the superiority of the combined model.
conclusionNomograms based on ultrasound radiomics and clinical features effectively distinguish DN stages non-invasively. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.